Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Dimatteo

Psychiatry Lisle, IL Medical Doctor

NPI 1487601985 CMS profile 112117

5950 Lincoln Ave, Unit W, Lisle, IL 60532

Open in the dashboard

General payments

$6,503

374 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Dimatteo of Lisle, IL is reported in the CMS Open Payments database as having received $6,503 across 374 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,157 66
2024 General $1,124 55
2023 General $1,123 55
2022 General $866 44
2021 General $908 58
2020 General $670 53
2019 General $656 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Dimatteo
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Thomas Dimatteo were reported at $1,157. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Thomas Dimatteo Psychiatry median Middle half National median
2019 $656 $184 $59–$605 $163
2020 $670 $119 $36–$372 $114
2021 $908 $143 $43–$576 $132
2022 $866 $153 $50–$590 $149
2023 $1,123 $170 $56–$651 $160
2024 $1,124 $179 $57–$673 $164
2025 $1,157 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $857 47 payments
  2. Corium, Inc. $710 43 payments
  3. Harmony Biosciences LLC $563 28 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $504 29 payments
  5. Tris Pharma Inc $412 28 payments
  6. Lundbeck LLC $406 26 payments
  7. Allergan Inc. $344 31 payments
  8. Otsuka America Pharmaceutical, Inc. $312 16 payments
  9. Almatica Pharma LLC $283 12 payments
  10. Ironshore Pharmaceuticals Inc. $242 11 payments
  11. Other $1,870 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,503 374 payments
Products named General payments · program years 2019–2025
  1. Azstarys $710 43 payments
  2. VRAYLAR Neuroscience $683 38 payments
  3. VRAYLAR Neuroscience $511 39 payments
  4. REXULTI Psychiatry $317 20 payments
  5. WAKIX Sleep Medicine $317 15 payments
  6. TRINTELLIX $308 16 payments
  7. REXULTI Psychiatry $290 15 payments
  8. LOREEV XR $283 12 payments
  9. Wakix Neurological Disorders $246 13 payments
  10. Dyanavel XR $186 8 payments
  11. Other $3,127 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

1,378

Median for Psychiatry & Neurology: 100

Drug cost

$78,983

Median for Psychiatry & Neurology: $2,986

Branded share of claims

16%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 14 $25,085
Nuedexta Dextromethorphan Hbr/Quinidine Brand 12 $17,598
Levocarnitine Generic 13 $3,403
Clozapine Generic 48 $2,621
Fluoxetine Hcl Generic 143 $2,306
Propranolol Hcl Generic 61 $2,272
Adderall Xr Dextroamphetamine/Amphetamine Brand 11 $2,189
Divalproex Sodium Generic 45 $2,066
Paliperidone Er Paliperidone Brand 13 $1,927
Quetiapine Fumarate Generic 22 $1,708

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
$258 — —
VRAYLAR
$188 14 —
LOREEV XR
$156 — —
REXULTI
$108 — —
Dyanavel XR
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record